Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer

Journal of Clinical Oncology

Volumn 33, Issue 9, 2015, Pages 969-971

  Tung, Nadine M ^a   Winer, Eric P ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC METAL COMPLEX; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; PROGRAMMED DEATH 1 LIGAND 1; SILVER; TAXANE DERIVATIVE; ERBB2 PROTEIN, HUMAN;

ALLELIC IMBALANCE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CAUSE OF DEATH; CD8+ T LYMPHOCYTE; CLINICAL ASSESSMENT; CYTOTOXICITY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DNA REPAIR; DOSE DENSIFICATION; DOUBLE STRANDED DNA BREAK; DRUG RESPONSE; EDITORIAL; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; HOMOLOGOUS RECOMBINATION; HUMAN; KIDNEY CANCER; LYMPHOCYTIC INFILTRATION; LYMPHOMA; MELANOMA; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PATIENT RISK; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE TRANSITION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; T LYMPHOCYTE; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; VALIDATION STUDY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BIOSYNTHESIS; FEMALE; METABOLISM; PROCEDURES; TRIPLE NEGATIVE BREAST NEOPLASMS;

CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84927142845     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.6031     Document Type: Editorial

References (38)

1. von Minckwitz G, Schneeweiss A, Loibl S, et al: Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol 15:747-756, 2014
2. Sikov WM, Berry DA, Perou CM, et al: Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dosedense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 33:13-21, 2015
3. Byrski T, Huzarski T, Dent R, et al: Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 147:401-405, 2014
4. Von Minckwitz G, Hahnen E, Fasching PA, et al: Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto. J Clin Oncol 32:48s, 2014 (suppl; abstr 1005)
5. Telli ML, Jensen KC, Kurian AW, et al: PrECOG 0105: Final efficacy results from a phase II study of gemcitabine (G) and carboplatin (C) plus iniparib (BSI-201) as neoadjuvant therapy for triple negative (TN) and BRCA1/2 mutation-associated breast cancer. J Clin Oncol 31:49s, 2013 (suppl; abstr 1003)
6. Silver DP, Richardson AL, Eklund AC, et al: Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 28:1145-1153, 2010
7. Birkbak NJ, Wang ZC, Kim JY, et al: Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2:366-375, 2012
8. Wang ZC, Birkbak NJ, Culhane AC, et al: Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res 18:5806-5815, 2012
9. Popova T, Manié E, Rieunier G, et al: Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 72:5454-5462, 2012
10. Vollebergh MA, Lips EH, Nederlof PM, et al: An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 22:1561-1570, 2011
11. Telli M, Jensen KC, Abkevich V, et al: Homologous recombination deficiency (HRD) score predicts pathologic response following neoadjuvant platinumbased therapy in triple-negative and BRCA1/2 mutation associated breast cancer. Cancer Res 72, 2012 (suppl; abstr PD09-04)
12. Loi S, Sirtaine N, Piette F, et al: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31:860-867, 2013
13. Adams S, Gray RJ, Demaria S, et al: Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32:2959-2966, 2014
14. Loi S, Michiels S, Salgado R, et al: Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol 25:1544-1550, 2014
15. Denkert C, Loibl S, Noske A, et al: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105-113, 2010
16. Yamaguchi R, Tanaka M, Yano A, et al: Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol 43:1688-1694, 2012
17. West NR, Milne K, Truong PT, et al: Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 13:R126, 2011
18. Bianchini G, Gianni L: The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol 15:e58-e68, 2014
19. Seo AN, Lee HJ, Kim EJ, et al: Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 109:2705-2713, 2013
20. Mahmoud SM, Paish EC, Powe DG, et al: Tumor-infiltrating CD8- lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29:1949-1955, 2011
21. Liu S, Foulkes WD, Leung S, et al: Prognostic significance of FOXP3- tumor infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res 16:432, 2014
22. Desmedt C, Haibe-Kains B, Wirapati P, et al: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14:5158-5165, 2008
23. Ignatiadis M, Singhal SK, Desmedt C, et al: Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: A pooled analysis. J Clin Oncol 30:1996-2004, 2012
24. Lehmann BD, Bauer JA, Chen X, et al: Identification of human triplenegative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750-2767, 2011
25. Denkert C, von Minckwitz G, Brase JC, et al: Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 33:983-991, 2015
26. Turner NC, Reis-Filho JS: Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25:5846-5853, 2006
27. Obeid M, Tesniere A, Ghiringhelli F, et al: Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54-61, 2007
28. Zitvogel L, Apetoh L, Ghiringhelli F, et al: Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8:59-73, 2008
29. Dieci MV, Criscitiello C, Goubar A, et al: Prognostic value of tumorinfiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multicenter study. Ann Oncol 25:611-618, 2014
30. Vincent J, Mignot G, Chalmin F, et al: 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 70:3052-3061, 2010
31. Roselli M, Cereda V, di Bari MG, et al: Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology 2:e27025, 2013
32. Jäger D, Jäger E, Knuth A: Immune responses to tumour antigens: Implications for antigen specific immunotherapy of cancer. J Clin Pathol 54:669-674, 2001
33. Schreiber RD, Old LJ, Smyth MJ: Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331:1565-1570, 2011
34. Loi S, MacCallum P: Host antitumor immunity plays a role in the survival of patients with newly diagnosed triple-negative breast cancer. J Clin Oncol 32:2935-2937, 2014
35. Mittendorf EA, Philips AV, Meric-Bernstam F, et al: PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2:361-370, 2014
36. Schalper KA, Velcheti V, Carvajal D, et al: In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 20:2773-2782, 2014
37. Mikami Y, Ueno T, Yoshimura K, et al: Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 ring study. Cancer Sci 104:1539-1543, 2013
38. Salgado R, Denkert C, Demaria S, et al: The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Ann Oncol [epub ahead of print on September 11, 2014]